-
ABOUT US
-
R&D
-
AGORA
-
PR
-
RECRUITMENT
-
CONTACT
AGORA
Patent
Patent status
It is a unique, first-in-class technology that uses ApoB100 as the molecular target for a new MOA obesity immunotherapy treatment.
Patents: Total 25 [6 Registered, 19 Applications]
| No. | Patents | Date | Country | Title |
|---|---|---|---|---|
| 1 | 10-2261457-00-00 | 2021 | KOREA | A PEPTIDE USED FOR IMMUNOTHERAPEUTICS |
| 2 | 11,952,414 | 2024 | USA | A PEPTIDE USED FOR IMMUNOTHERAPEUTICS |
| 3 | 2836172 | 2025 | RUSSIA | A PEPTIDE USED FOR IMMUNOTHERAPEUTICS |
| 4 | 2021311894 | 2025 | AUSTRALIA | PEPTIDE FOR IMMUNOTHERAPEUTIC AGENT |
| 5 | 7746284 | 2025 | JAPAN | A PEPTIDE USED FOR IMMUNOTHERAPEUTICS |
| 6 | 12,479,905 | 2025 | USA | A PEPTIDE USED FOR IMMUNOTHERAPEUTICS |